Drug Trial Radar · NCT06702605
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Nov 2024
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Evopoint Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R/R PTCL. The study plans to enroll approximately 50 subjects.
Conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
Interventions
XNW5004 tabletsDrug
XNW5004 will be administered orally as tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) assessed by independent review committee (IRC)Time frame: 24 mounths
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.